Abstract
The 14th Japan Bioanalysis Forum Symposium was held at Tower Hall Funabori, Japan from 1–3 March 2023. The conference theme, ‘Bringing Together – the Expertise of Bioanalysis’, aimed to enable people from various fields to gather, learn and collaborate together for the common goal of delivering medicines to patients faster. Approximately 360 participants from various fields, including pharmaceutical industries, contractors, academia and regulatory authorities, gathered at an in-person symposium which had an online participation option, for the first time in 4 years. The symposium offered a wide range of topics including ICH M10, new modalities, biomarkers, immunogenicity, electronization and patient-centric sampling. The latest research results were provided from domestic and overseas scientists. This report summarizes the major topics.
Author contributions
T Arakawa: Symposium chair, construction of subparts, writing (original draft, review). Y Nishiguchi: symposium co-chair, construction of subparts, writing (original draft, review). M Hashimoto, M Mabuchi, N Koyama, M Niwa, T Yamaguchi, R Yoshinaga, Y Takamatsu, J Komaba, T Nakamura, T Saito, Y Ohtsu, M Takahashi, R Yagi, S Hanari, Y Hashimoto and S Uchihashi: construction of subparts, writing (original draft, review).
Acknowledgments
The authors thank all presenters for their contribution to an interactive and productive symposium.
Financial disclosure
The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Competing interests disclosure
The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Writing disclosure
No writing assistance was utilized in the production of this manuscript.